Penederm, UCB deal

DERM and a subsidiary of UCB will develop topical prescription nail antifungal formulations of DERM’s KP363 product in Europe, the Middle East, Africa and several other countries. DERM received an undisclosed upfront payment and will receive milestones and royalties.

The agreement includes a license to market DERM’s KP363 topical nail fungal formulations, which combine butenafine with DERM’s TopiCare Delivery Compounds. ...